Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren 300 mg add-on therapy for diabetic macular edema
2008-000581-23Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic macular edema (DME) comparing Aliskiren 300 mg add-on with Placebo add-on (2 arms). Primary endpoint: Primary: Change in central retinal thickness. Started Jul 2008; status: completed.
02
Drugs
aliskiren
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2008-000581-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000581-23.